These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 2211021)

  • 1. Intraocular radiation blocking.
    Finger PT; Ho TK; Fastenberg DM; Hyman RA; Stroh EM; Packer S; Perry HD
    Invest Ophthalmol Vis Sci; 1990 Sep; 31(9):1724-30. PubMed ID: 2211021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose rate effect of 125I irradiation on normal rabbit eyes and experimental choroidal melanoma.
    Yang CM; Olsen KR; Schwade JG; Houdek PV; Markoe AM; Pisciotta V; Wu X
    Exp Eye Res; 1993 Nov; 57(5):577-85. PubMed ID: 8282044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of iodine 125 radiation with vitreous substitutes in the treatment of uveal melanoma.
    Oliver SC; Leu MY; DeMarco JJ; Chow PE; Lee SP; McCannel TA
    Arch Ophthalmol; 2010 Jul; 128(7):888-93. PubMed ID: 20625051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement.
    Morrison H; Larocque MP; Menon G; Sloboda RS; Weis E
    Brachytherapy; 2019; 18(5):668-674. PubMed ID: 31272841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma.
    Jensen AW; Petersen IA; Kline RW; Stafford SL; Schomberg PJ; Robertson DM
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):101-8. PubMed ID: 16111577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the shielding effectiveness of silicone oil vitreous substitutes when used with Palladium-103 and Iodine-125 eye plaques.
    Yang YM; Chow PE; McCannel TA; Lamb JM
    Med Phys; 2019 Feb; 46(2):1006-1011. PubMed ID: 30554429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palladium 103 ophthalmic plaque radiotherapy.
    Finger PT; Moshfeghi DM; Ho TK
    Arch Ophthalmol; 1991 Nov; 109(11):1610-3. PubMed ID: 1755746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved treatment planning for COMS eye plaques.
    Astrahan MA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1227-42. PubMed ID: 15752905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dose to the surgeon during plaque brachytherapy.
    Classic KL; Furutani KM; Stafford SL; Pulido JS
    Retina; 2012 Oct; 32(9):1900-5. PubMed ID: 22487580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palladium-103 plaque radiotherapy for choroidal melanoma: results of a 7-year study.
    Finger PT; Berson A; Szechter A
    Ophthalmology; 1999 Mar; 106(3):606-13. PubMed ID: 10080222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
    Toivonen P; Kivelä T
    Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study randomized trials: COMS report no. 22.
    Collaborative Ocular Melanoma Study Group
    Ophthalmology; 2004 May; 111(5):966-76. PubMed ID: 15121376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetry and physical treatment planning for iodine eye plaque therapy.
    Alberti W; Pothmann B; Tabor P; Muskalla K; Hermann KP; Harder D
    Int J Radiat Oncol Biol Phys; 1991 May; 20(5):1087-92. PubMed ID: 2022510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.
    Kim H; Robinson MR; Lizak MJ; Tansey G; Lutz RJ; Yuan P; Wang NS; Csaky KG
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2722-31. PubMed ID: 15277497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation dose profile in 125I brachytherapy: an 8-year review.
    Al-Haj AN; Lobriguito AM; Lagarde CS
    Radiat Prot Dosimetry; 2004; 111(1):115-9. PubMed ID: 15367781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetry and design of radioactive eye plaques.
    Flühs D; Bambynek M; Heintz M; Indenkämpen F; Kolanoski H; Wegener D; Sauerwein W; Quast U
    Front Radiat Ther Oncol; 1997; 30():26-38. PubMed ID: 9205882
    [No Abstract]   [Full Text] [Related]  

  • 17. [Development and dosimetry of a 125 iodine applicator for brachytherapy of intraocular tumors].
    Alberti W; Pothmann B; Bornfeld N; Foerster MH; Harder D; Hermann KP; Muskalla K; Tabor P; Sack H; Wessing A
    Fortschr Ophthalmol; 1990; 87(2):201-5. PubMed ID: 2358279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermoradiotherapy of intraocular tumors in an animal model: concurrent vs. sequential brachytherapy and ferromagnetic hyperthermia.
    Steeves RA; Tompkins DT; Nash RN; Blair JR; Gentry LL; Paliwal BR; Murray TG; Mieler WF
    Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):659-62. PubMed ID: 7558956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.
    Mieler WF
    Trans Am Ophthalmol Soc; 1997; 95():611-28. PubMed ID: 9440189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
    Puusaari I; Heikkonen J; Kivelä T
    Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.